Elena V. Derkach

Elena V. Derkach

Auto-generated profile, based on publicly available information

Elena V. Derkach

National Center for Healthcare Technology Assessment

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2023 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
VIV.I. Ignatyeva
V.I. Ignatyeva
I(Igor Voznyuk (Voznjouk)
Igor Voznyuk (Voznjouk)
NSN.A. Shamalov
N.A. Shamalov
ARA.V. Reznik
A.V. Reznik
AVA.A. Vinitskiy
A.A. Vinitskiy
EDE.V. Derkach
E.V. Derkach
Objective. The purpose of this study was to assess the annual socio-economic burden of stroke in the Russian Federation from the position of the state. Material and methods. Based on official statistics on morbidity and mortality due to stroke (2019), the results of a survey of patients or caregivers (680 respondents) and cost indicators of 2022, the social and economic burden of stroke during the 1st year after the acute period is modeled. All cost estimates are made from the position of the state. Results. In 2019 435.2 thousand cases of stroke have been registered in the Russian Federation, 30% of those patients died during the year after the acute episode, thus annually up to 1.7 million years of life are lost. According to our study, stroke accounted for 2% of all days of disability paid by Social Insurance Fund in 2019 and 9% of cases of primary receiving of disability. More than 139 thousand working people assisted their relatives who suffered a stroke, 59.2 thousand of them were forced to change jobs, 18 thousand people left work due to the need to care for a relative. The economic burden of stroke amounted to more than 490 billion rubles. or 0.3% of GDP. The average costs per 1 registered case of hemorrhagic stroke amounted to 0.93 million rubles, ischemic — 1.2 million rubles, of which about 10% are medical costs, 5% are non-medical costs and 85% are costs associated with loss of productivity. Conclusion. Stroke causes a significant socio-economic burden for the state in the Russian Federation, the economic losses within 1 year is equal to the 0.3% of the country’s annual GDP. The main contribution to the stroke economic and social burden is not only mortality, but also disability, leading to incapacitation of patients who have suffered a stroke, as well as to a reduction in the contribution to the economy of their relatives who help and care for them.

16 July 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
SBSergey Boytsov
Sergey Boytsov
VOV. V. Omelyanovskiy
V. V. Omelyanovskiy
AKA. V. Kontsevaya
A. V. Kontsevaya
MLM. M. Loukianov
M. M. Loukianov
EDE. V. Derkach
E. V. Derkach
Heart failure (HF) significantly worsens the patient quality of life and leads to the disability of their significant part, as well as increases the risk of death, which in turn causes economic damage.Aim. To assess the annual socio-economic impact of HF in Russia.Material and methods. To assess the socio-economic impact of HF, a model was developed, which assessed the number of HF patients seeking medical care (data from the epidemiological studies), the number of those with disabilities and the mortality rate among them. We also evaluated the costs of drug therapy (data from the government procurement reports) and hospitalization (data from the compulsory health insurance tariffs), social benefits due to disability, and death impact on the gross domestic product. Data on the prescription rate, hospitalizations and mortality was obtained from Russian registries of patients with cardiovascular diseases. Using the foreign study, the costs of family caregiving were also calculated.Results. According to modeling data, there are 7,1 million people with HF seeking medical care in Russia. In this case, the annual economic impact of HF in the context of government spending, is RUB 81,86 billion, including medical costs of RUB 18,6 billion, direct nonmedical costs of RUB 47,1 billion, and indirect costs of RUB 16,2 billion. The impact of family caregiving is RUB 72,4 billion. In the structure of medical expenses, 73,6% is hospitalization costs, while the main costs of drug therapy are borne by patients, since only a part of them (19,6%) receive the necessary medications within assistance programs. In patients with HF with reduced ejection fraction, medical costs are 56% higher than in patients with HF with preserved ejection fraction.Conclusion. HF causes significant economic burden to the state. Improving the healthcare system for this category of patients, including preferential drug provision, will reduce HF-related mortality, the healthcare system costs and, accordingly, reduce the economic impact on the state and society.

1 October 2018 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Open access
NANikolay Avxentyev
Nikolay Avxentyev
EDElena Derkach
Elena Derkach
AMAlexander Makarov
Alexander Makarov
DOI: https://doi.org/10.31556/2219-0678.2018.33.3.062-074 meta Аннотация Энзалутамид, абиратерон в комбинации с преднизолоном и кабазитаксел в комбинации с преднизолоном (далее абиратерон и кабазитаксел соответственно) одобрены в России для лечения метастатического кастрационно-резистентного рака предстательной железы (мКРРПЖ) у пациентов, ранее получавших химиотерапию. В настоящее время ни один из указанных лекарственных препаратов не входит в программу обеспечения необходимыми лекарственными средствами (ОНЛС). Целью исследования является проведение фармакоэкономческого анализа применения энзалутамида, абиратерона и кабазитаксела у данной категории пациентов с позиции российской системы здравоохранения. Материал и методы. На основе данных клинических исследований AFFIRM (энзалутамид), COU-AA-301 (абиратерон) и TROPIC (кабазитаксел), а также выполненного авторами непрямого сравнения рассматриваемых альтернатив, была предложена марковская модель развития мКРРПЖ при использовании различных вариантов лекарственной терапии, на основе которой были рассчитаны прямые медицинские расходы за период 5 лет. Было проведено три вида фармакоэкономического анализа: «влияние на бюджет», «затраты-эффективность» и «затраты-полезность». Результаты. Среднее число прожитых человеко-лет с поправкой на качество жизни при применении энзалутамида, абиратерона и кабазитаксела составляет 1,04, 0,94 и 0,96 лет соответственно. Стоимость месячного курса терапии энзалутамидом составляет 183 550,71 рублей, что на 15% меньше, чем стоимость месячного курса терапии абиратероном, и на 49% меньше по сравнению с терапией кабазитакселом. При использовании энзалутамида прямые медицинские расходы в расчете на одного пациента за 5 лет составляют 3 330 982 рублей против 3 331 998 рублей в случае использования абиратерона и 4 434 624 рублей в случае использования кабазитаксела. Снижение относительной разницы в затратах объясняется лучшей выживаемостью без прогрессирования при использовании энзалутамида по сравнению с абиратероном и кабазитакселом. При включении энзалутамида в программу ОНЛС расходы бюджета Программы государственных гарантий за пять лет составят 6 524,6 млн рублей, что ниже, чем в случае включения абиратерона (6 526,6 млн руб.) или кабазитаксела (8 688,4 млн руб.). Выводы. По сравнению с абиратероном и кабазитакселом, энзалутамид является более эффективным вариантом терапии пациентов с мКРРПЖ после химиотерапии, а его применение требует таких же или меньших дополнительных расходов системы здравоохранения. Ключевые слова рак предстательной железы, энзалутамид, абиратерон, кабазитаксел, фармакоэкономический анализ, анализ «затраты-эффективность», анализ «затраты-полезность», влияние на бюджет. Для цитирования Авксентьев Н. А., Деркач Е. В., Макаров А. С. Фармакоэкономическое исследование применения энзалутамида, абиратерона и кабазитаксела после химиотерапии у пациентов с метастатическим кастрационно-резистентным раком предстательной железы. Медицинские технологии. Оценка и выбор. 2018; 3(33): 62–74.

6 March 2025 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
MSM.V. Sura
M.V. Sura
IDI.A. Demidova
I.A. Demidova
OIO.A. Ignatenko
O.A. Ignatenko
GRG.A. Raskin
G.A. Raskin
GSG.R. Setdikova
G.R. Setdikova
EDE.V. Derkach
E.V. Derkach
Objective. To analyze the system of organization and payment for molecular genetic testing used for diagnosis of six most common malignancies in certain constituent entities of the Russian Federation and to improve its effectiveness. Material and methods. We prepared a list of molecular genetic tests specified in current versions of clinical guidelines for six most common malignancies: cancer of bronchi and lungs (C34), breast cancer (C50), ovarian cancer (C56), prostate cancer (C61), pancreatic cancer (C25), and chronic lymphocytic leukemia (C91.1). Information on scheduled volumes of molecular genetic testing and tariffs was extracted from territorial programs of state guarantees for free care to citizens for 2023-2025, as well as from tariff agreements in compulsory medical insurance system in 8 constituent entities of the Russian Federation (Moscow, Moscow Region, St. Petersburg, Sverdlovsk Region, Novosibirsk Region, Primorsky Krai, Khabarovsk Krai, Amur Region). We surveyed 8 experts from constituent entities of the Russian Federation (managers, heads or employees of diagnostic laboratories, pathology departments) regarding availability of molecular genetic tests for patients with certain malignancies, organization, payment for them and proposals for its improvement. Results. In 8 constituent entities of the Russian Federation, various outpatient molecular genetic tests are performed at the expense of compulsory medical insurance funds in accordance with clinical recommendations. The largest number of tests are performed to diagnose malignant neoplasms of bronchi and lungs, breast cancer and ovarian cancer. The planned number of services established in regions for outpatient molecular genetic tests correspond to federal standards or exceed them. In some regions with well-equipped laboratories with sufficient capacity, molecular genetic tests are performed for other constituent entities of the Russian Federation. The number of such procedures comprises 30-60% of all ones in the region, and payment is made through interterritorial and/or interinstitutional transactions. There is significant interterritorial differentiation in tariffs for the same molecular genetic tests. This may be due to reagents, consumables and equipment. According to experts, higher efficiency of system for organizing and paying for molecular genetic testing in oncology can be associated with federal legislative and organizational initiatives. These are approval of rules for molecular genetic testing, development of a unified methodology for compulsory medical insurance tariffs for outpatient molecular genetic testing at the federal level, approval of new nomenclature of medical services, accelerated registration of reagents and consumables. Another approach is management decisions at the level of regions (increased planned number of outpatient molecular genetic testing, expanding the list of compulsory medical insurance tariffs for molecular genetic testing, annual indexation of tariffs and their compliance with actual expenses incurred). Conclusion. A comprehensive analysis of data from 8 constituent entities of the Russian Federation revealed achievements and certain problems in organizing and paying for molecular genetic testing. The solution of the problems requires some measures to unify approaches to such testing and their pricing at the federal and regional levels.

20 June 2025 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
VIV.I. Ignatyeva
V.I. Ignatyeva
Marat EzhovMarat Ezhov
Marat Ezhov
AKA.V. Kontsevaya
A.V. Kontsevaya
FPF.N. Paleev
F.N. Paleev
EDE.V. Derkach
E.V. Derkach
ODOxana M. Drapkina
Oxana M. Drapkina
Objective. To assess the social and economic damage caused by the elevated low-density lipoprotein cholesterol (LDL-C) in the Russian Federation population from the state’s standpoint. Material and methods. Based on the ESSE-RF study data on the LDL-C level and the literature data on the corresponding relative risk, the population attributable fraction (PAF) of this risk factor for coronary heart disease (CHD) and ischemic stroke in the population under the age of 65 years was calculated. The social and economic damage caused by LDL-C is modeled as a proportion equal to the PAF of the CHD and ischemic stroke socio-economic burden in Russia for this age group. The probable damage value associated with LDL-C in persons 65 years and older was also calculated. Results. Elevated LDL-C levels in persons younger than 65 years account for more than half of ischemic stroke and CHD, including myocardial infarction, as well as a reduction in life expectancy by 0.7 years in males and 0.3 years in females. The annual medical costs associated with these diseases amounted to 51.4 billion rubles, and the social costs amounted to 29.0 billion rubles. The annual damage to gross domestic product (GDP) is estimated at 209.1 billion rubles. Considering all the lost «economically active» years, the GDP damage exceeds 1 trillion rubles. The estimated contribution of LDL-C to the annual damage associated with coronary heart disease and ischemic stroke in the age group of individuals 65 years and older is estimated at 78.9 billion rubles, including 62.5 billion rubles in medical and social care costs. Conclusion. Significant socio-economic damage caused by elevated low-density lipoprotein cholesterol levels indicates the need for preventive measures to control this risk factor, starting at a young age.

8 December 2023 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
EPE.A. Pyadushkina
E.A. Pyadushkina
VIV.I. Ignatieva
V.I. Ignatieva
EYE.E. Yagnenkova
E.E. Yagnenkova
EDE.V. Derkach
E.V. Derkach
Objective. Cost-effectiveness analysis of anifrolumab therapy in adults with moderate-to-severe systemic lupus erythematosus in the Russian Federation. Material and methods. We performed cost-effectiveness analysis to assess incremental cost-effectiveness ratio (ICER) for anifrolumab compared to belimumab in addition to standard therapy. Considering the results of indirect comparison, we established the criteria of effectiveness. Analysis of costs was based on government procurement of drugs and registered prices of drugs from the list of vital and essential drugs. Dosages of drugs were determined in accordance with instructions and clinical recommendations. Finally, we performed a sensitivity analysis varying the input parameters. Results. Anifrolumab has a significant advantage in effectiveness compared to belimumab. The odds ratio for response to therapy (SRI-4 criterion) is 2.61 (95% CI 1.22—5.58). The cost of 52-week anifrolumab therapy in addition to standard therapy is 1.3 million rubles per a patient, the cost of belimumab therapy — 0.62 million rubles. Additional costs per a patient with SRI-4 response (ICER) amounted to 3.49 million rubles when using anifrolumab compared to belimumab. This value is lower than ICER for belimumab in addition to standard therapy compared to standard therapy (5.08 million rubles). Sensitivity analysis demonstrates robustness of results to varyability of input values. Conclusion. Clinical effectiveness of anifrolumab therapy is significantly higher compared to belimumab according to SRI-4 criterion, but this therapy requires greater costs. Incremental cost for achieving SRI-4 response in 1 additional patient is 31.15% lower for anifrolumab compared to belimumab than for belimumab compared to standard therapy. Therefore, anifrolumab therapy is economically feasible in patients with moderate-to-severe systemic lupus erythematosus.